A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 21,700 shares of CRDF stock, worth $45,136. This represents 0.0% of its overall portfolio holdings.

Number of Shares
21,700
Previous 39,200 44.64%
Holding current value
$45,136
Previous $58,000 98.28%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$1.46 - $5.91 $25,550 - $103,425
-17,500 Reduced 44.64%
21,700 $115,000
Q4 2023

Feb 14, 2024

SELL
$0.96 - $1.55 $1,728 - $2,790
-1,800 Reduced 4.39%
39,200 $58,000
Q3 2023

Nov 14, 2023

SELL
$1.38 - $2.18 $181,884 - $287,324
-131,800 Reduced 76.27%
41,000 $56,000
Q2 2023

Aug 14, 2023

BUY
$1.37 - $1.95 $40,141 - $57,135
29,300 Added 20.42%
172,800 $254,000
Q1 2023

May 15, 2023

SELL
$1.45 - $2.09 $62,930 - $90,706
-43,400 Reduced 23.22%
143,500 $236,000
Q4 2022

Feb 14, 2023

SELL
$1.22 - $1.59 $11,712 - $15,264
-9,600 Reduced 4.89%
186,900 $261,000
Q3 2022

Nov 14, 2022

SELL
$1.57 - $3.21 $217,131 - $443,943
-138,300 Reduced 41.31%
196,500 $303,000
Q2 2022

Aug 15, 2022

SELL
$1.17 - $2.61 $209,781 - $467,973
-179,300 Reduced 34.88%
334,800 $737,000
Q1 2022

May 16, 2022

SELL
$2.11 - $7.25 $318,399 - $1.09 Million
-150,900 Reduced 22.69%
514,100 $1.28 Million
Q4 2021

Feb 14, 2022

SELL
$5.18 - $7.24 $185,444 - $259,192
-35,800 Reduced 5.11%
665,000 $4 Million
Q3 2021

Nov 15, 2021

BUY
$5.01 - $7.58 $178,356 - $269,848
35,600 Added 5.35%
700,800 $4.67 Million
Q2 2021

Aug 16, 2021

BUY
$6.65 - $10.04 $527,345 - $796,171
79,300 Added 13.53%
665,200 $4.42 Million
Q1 2021

May 17, 2021

BUY
$9.1 - $19.57 $4.26 Million - $9.15 Million
467,600 Added 395.27%
585,900 $5.43 Million
Q4 2020

Feb 16, 2021

BUY
$12.02 - $24.71 $1.42 Million - $2.92 Million
118,300 New
118,300 $2.13 Million

Others Institutions Holding CRDF

About Cardiff Oncology, Inc.


  • Ticker CRDF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,334,900
  • Market Cap $90.1M
  • Description
  • Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...
More about CRDF
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.